Bayer backs FY19 sales of around EUR46B, up approximately 4% y/y

Bayer has confirmed the forecasts for 2019 and the medium-term targets for 2022 that it provided in conjunction with its Capital Markets Day on December 5, 2018. For 2019, the company expects sales to amount to around 46 billion euros. This corresponds to an increase of approximately 4 percent. Bayer aims to increase EBITDA before special items to approximately 12.2 billion euros, while core earnings per share are seen rising to approximately 6.80 euros. These targets do not take into account changes in exchange rates or the plans to exit the Animal Health business unit, divest the Consumer Health brands Coppertone and Dr. Scholl’s, and sell the 60-percent interest in German site services provider Currenta. For Crop Science, Bayer sees 2019 sales rising by around 4 percent and anticipates an EBITDA margin before special items of approximately 25 percent. For Pharmaceuticals, Bayer expects sales to rise by approximately 4 percent and the EBITDA margin before special items to increase to around 34 percent. For Consumer Health, the company aims to increase sales by approximately 1 percent and to achieve an EBITDA margin before special items of around 21 percent. For Animal Health, Bayer also expects sales to increase by around 4 percent and aims to achieve an EBITDA margin before special items of approximately 24 percent.

https://thefly.com/landingPageNews.php?id=2870959